x.org/research_MJFFfundingPortfolio_searchableAwardedGrants.cfm">Searchable Database of Funded Grants at www.michaeljfox.org/research
. As with all MJFF grants, full funding is contingent on the achievement of predetermined, specific milestones and on researchers' agreement to make the results of their work available to the Parkinson's research community.
Projects Focused on Inflammation and Oxidative Stress
Design of Neuroprotective Drugs to Reduce Oxidative Damage and Alpha-Synuclein Toxicity in Parkinson's Disease
Stig Hansen, Ph.D., Carmot Therapeutics, Inc.
Targeting TLR2 as a Novel Therapy for Parkinson's Disease
Andrew Parker, Ph.D., Opsona Therapeutics LTD
An Innovative Drug for Disease-Modifying Treatment of Parkinson's Disease
Philipp Wabnitz, Ph.D., InterMed Discovery GmbH
Projects Focused on Alpha-Synuclein
Determination and Validation of the Molecular Target of J3, a Neuroprotective Lead Compound, for Its Optimization as a Disease-modifying Candidate for Parkinson's Disease
Christine Bulawa, Ph.D., FoldRx Pharmaceuticals, Inc.
Developing Autophagy Enhancers as Disease-modifying Therapeutics for Parkinson's Disease
John Dunlop, Ph.D., Pfizer Global Research and Development
Potential Efficacy of a Novel, Orally Bioavailable, CNS-penetrant HDAC Inhibitor in Pre-clinical Models of Parkinson's Disease
Page: 1 2 3 Related medicine technology :1
|SOURCE Michael J. Fox Foundation|
Copyright©2010 PR Newswire.
All rights reserved
. D-M-S Holdings, Inc. Announces the Filing of a Lawsuit Against Veridian Healthcare, LLC, Steven M. Bisulca and Michael Mazza2
. Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting3
. Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences4
. Sigma-Aldrich(R) Receives Award From Michael J. Fox Foundation to Develop Parkinsons Disease Research Models5
. Michael J. Fox Foundation-Funded Team Pursuing Glutamate-Based Treatment for Parkinsons Disease Hits Major Milestone6
. Michael J. Fox Foundation Commits Up to $12 Million for Targeted Parkinsons Therapeutic Development in 20107
. Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs8
. Michael J. Fox Foundation Awards Over $2 Million for Validation of 10 Parkinsons Therapeutic Targets9
. Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinsons Disease10
. Michael J. Fox Foundation Awards $2.1 Million to Improve Drug Delivery in Parkinsons Disease11
. Michael J. Fox Foundation Awards $2.9 Million for Two New Parkinsons Disease Clinical Trials